Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation and Phototoxicity Study of KX01 Ointment 1%
NCT05245578Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirbanibulin in actinic keratosis (AK), sponsored by PharmaEssentia. Primary endpoints: Degree of skin irritation at application site at 9 days and Phototoxic potential at application site at 9 days. Started Nov 2021; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05245578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245578.